Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

December 31, 2009

Conditions
AML
Interventions
DRUG

Obatoclax

A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.

Trial Locations (13)

10011

St. Vincent's Comprehensive Cancer Center, New York

17033

Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey

48106

St. Joseph Mercy Hospital, Ann Arbor

48109

University of Michigan Health System, Ann Arbor

48910

Michigan State University - Breslin Cancer Center, Lansing

52242

The University of Iowa, Iowa City

60611

Northwestern University, Chicago

66205

University of Kansas Medical Center Research Institute, Westwood

77030

MD Anderson Cancer Center, Houston

97210

Legacy Emanuel Hospital & Health Center, Portland

98101

Benaroya Research Institute at Virginia Mason, Seattle

02115

Dana Farber Cancer Institute, Boston

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gemin X

INDUSTRY

NCT00684918 - Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter